Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: Results from 2 clinical trials

: Combe, B.; Behrens, F.; McHugh, N.; Brock, F.; Kerkmann, U.; Kola, B.; Gallo, G.


The Journal of Rheumatology 43 (2016), Nr.6, S.1063-1067
ISSN: 0315-162X
Fraunhofer IME ()


Objective. To evaluate the clinical/functional outcomes associated with etanercept (ETN) monotherapy versus combination therapy in psoriatic arthritis (PsA).

Methods. Data from patients with PsA who received ETN alone (n = 322) or combined with methotrexate (MTX; n = 152) for 24 weeks in 2 placebo-controlled clinical trials were summarized across studies.

Results. Similar proportions of patients in the monotherapy and combination therapy groups achieved the PsA Response Criteria (80% and 83%) and the American College of Rheumatology improvements of 20% (ACR20; both 70%); numerically higher proportions receiving monotherapy achieved ACR50 (55% vs 48%) and ACR70 (35% vs 27%). Little between-group difference was observed in the 28-joint Disease Activity Score with C-reactive protein, the Psoriasis Area and Severity Index, and the Health Assessment Questionnaire–Disability Index improvement.